The ongoing latter global clinical study in NSCLC patients with ALK-rearranged indicates that crizotinib gives a high RR, good PFS, modest toxicity, and improvement in patient-reported symptoms [105]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.